Meril Life Sciences is an Indian global medtech company. In Ukraine, we focus the page on heart valves, TAVR, coronary stents, balloon catheters and solutions for vascular access.
Meril's portfolio is divided by procedural areas so that the doctor can quickly navigate to the desired product group, catalog and detailed cards.
Surgical bioprosthesis and the transcatheter TAVR approach are presented as separate clinical routes.
To valves →
Sirolimus-eluting stents: basic, Morph and Branch configurations.
To stents →
Rx, NC and SEB for predilatation, postdilation and complex lesions.
To cylinders →
Intracoronary shunt for operation during anastomosis.
To card →
Absorbable and non-absorbable threads with IFU, brochures and individual clinical data.
To sutures →
Peripheral stenting, closure of vascular access and neurovascular embolization.
To the periphery →
The model range according to the manufacturer's classification. Selection of positions, size range and configuration — on request.
On the page, it is important not to mix all directions in one catalog: valves, TAVR, stents and balloons have different clinical logic, different documents and different procurement solutions.
Triple composite valve from bovine pericardium and elgiloy stent. Position-specific design for aortic and mitral position.
Minimally invasive aortic valve replacement for patients not indicated for open surgery.
Ultrathin sirolimus-eluting coronary stent with hybrid cell design.
A line of balloon catheters for the complete procedural cycle of angioplasty.
Absorbable and non-absorbable sutures are presented separately so that the surgeon can quickly compare the material, structure, USP size, needle, and position-specific evidence.
Bovine pericardium + elgiloy, patented anti-calcium treatment, unique delivery system for mitral position.
Hybrid honeycomb design with PET, supra-annular position and widest size range with RCT-level evidence base.
Ultrathin sirolimus-eluting stent, hybrid cell design, non-inferiority to XIENCE in meriT-V.
Antibacterial absorbable suture data from the Meril randomized controlled trial.
Meril's evidence materials are grouped by clinical area to quickly find documents for the exact procedure you need.
Randomized trial of 768 patients: primary composite endpoint 25% Myval vs 27% modern THV.
EOA 0.6→1.8 cm², mean gradient 47.4→12.0 mm Hg. art.; by 12 months there were no new PPMs.
BioMime has a 65 µm cobalt-chromium platform, BioPoly 2 µm and randomized meriT-V non-inferiority to XIENCE.
First-in-human study for aortic and mitral position, with gradient reduction and 3-year durability evaluation data.
Polyglactin 910 + Triclosan; randomized-controlled single-blind comparison with Vicryl Plus, 122 patients, follow-up up to 6 months.
IFU, brochures, size charts, CE/ISO, registration of the MOH of Ukraine and catalog codes for a specific model.
We will tell you the availability, size range and prices for the tender, we will send the specification and the evidence base for your list.